Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$146.58+2.23 (+1.54%)
Close on Nov 18, 2026Market cap $2.11BP/E –Yield –
Palvella Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Palvella Therapeutics's revenue for the twelve months ending Sep 30, 2024 was $1.35M, down 97.1% year over year. For fiscal 2023 it was $42.81M, up 65.3% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $46.28M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $42.81M | +65.3% |
| FY2022 | Dec 31, 2022 | $25.90M | -17.6% |
| FY2021 | Dec 31, 2021 | $31.42M | +7.1% |
| FY2020 | Dec 31, 2020 | $29.32M | -36.6% |
| FY2019 | Dec 31, 2019 | $46.28M | +59.0% |
| FY2018 | Dec 31, 2018 | $29.10M | +15.1% |
| FY2017 | Dec 31, 2017 | $25.28M | +333.5% |
| FY2016 | Dec 31, 2016 | $5.83M | +98.9% |
| FY2015 | Dec 31, 2015 | $2.93M | -45.4% |
| FY2014 | Dec 31, 2014 | $5.37M | -56.8% |
| FY2013 | Dec 31, 2013 | $12.43M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $53.00K | -97.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.30M | -77.8% |
| Q3 FY2023 | Sep 30, 2023 | $19.52M | +263.5% |
| Q2 FY2023 | Jun 30, 2023 | $20.06M | +442.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.94M | -82.4% |
| Q4 FY2022 | Dec 31, 2022 | $5.85M | -30.8% |
| Q3 FY2022 | Sep 30, 2022 | $5.37M | +32.4% |
| Q2 FY2022 | Jun 30, 2022 | $3.70M | +12.6% |
| Q1 FY2022 | Mar 31, 2022 | $10.99M | -29.7% |
| Q4 FY2021 | Dec 31, 2021 | $8.44M | +349.8% |
| Q3 FY2021 | Sep 30, 2021 | $4.06M | +38.0% |
| Q2 FY2021 | Jun 30, 2021 | $3.29M | -70.8% |
| Q1 FY2021 | Mar 31, 2021 | $15.63M | +17.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.88M | -89.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.94M | -80.6% |
| Q2 FY2020 | Jun 30, 2020 | $11.25M | +110.9% |
| Q1 FY2020 | Mar 31, 2020 | $13.26M | +55.2% |
| Q4 FY2019 | Dec 31, 2019 | $17.27M | +251.4% |
| Q3 FY2019 | Sep 30, 2019 | $15.13M | +81.3% |
| Q2 FY2019 | Jun 30, 2019 | $5.33M | -54.4% |
| Q1 FY2019 | Mar 31, 2019 | $8.55M | +105.8% |
| Q4 FY2018 | Dec 31, 2018 | $4.91M | -72.9% |
| Q3 FY2018 | Sep 30, 2018 | $8.35M | +112.5% |
| Q2 FY2018 | Jun 30, 2018 | $11.69M | +530.9% |
| Q1 FY2018 | Mar 31, 2018 | $4.15M | +209.2% |
| Q4 FY2017 | Dec 31, 2017 | $18.15M | +565.8% |
| Q3 FY2017 | Sep 30, 2017 | $3.93M | +400.3% |
| Q2 FY2017 | Jun 30, 2017 | $1.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.34M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.73M | – |
| Q3 FY2016 | Sep 30, 2016 | $785.01K | – |
See a number that looks wrong?